ALB and infection: In mice treated 9x with the PCN, the protection against a subsequent primary influenza virus infection was characterized by a significantly greater reduction in viral burdens by day 7 post-infection (Figure 3A), and by the absence of any weight loss (Figure 3B), and lung damage, as indicated by the decreased levels of albumin (Figure 3C) and lactate dehydrogenase (LDH) (Figure 3D) recovered from the broncho-alveolar lavage fluid (BALF) [11], [12].